Cargando…

Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma

The glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic antibody (DTA-1) has been proved to elicit robust immune response in various kinds of tumors. However, only a few of the HCC patients could benefit from it, and the mechanism of DTA-1 resistance remains unknown. Here, we meas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Caixu, Wu, Qinchuan, Wang, Shuai, Mei, Zhibin, Zhang, Lele, Gao, Xingxing, Qian, Junjie, Xu, Zhentian, Zhang, Ke, Su, Rong, Guo, Danjing, Zhou, Lin, Zheng, Shusen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090298/ https://www.ncbi.nlm.nih.gov/pubmed/35558158 http://dx.doi.org/10.1080/2162402X.2022.2073010

Ejemplares similares

Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response
por: Zhang, Lele, et al.
Publicado: (2021)

Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1 (+) CD8 (+) T cells in HCC via blocking VEGFR2
por: Mei, Zhibin, et al.
Publicado: (2023)

Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity
por: Liu, Huisi, et al.
Publicado: (2022)

Pharmacodynamic analysis of an agonistic antibody to the costimulatory receptor GITR
por: Moody, Gordon, et al.
Publicado: (2015)

An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy
por: Chan, Sarah, et al.
Publicado: (2022)

Nanosecond Pulsed Electric Field Induces an Antitumor Effect in Triple-Negative Breast Cancer via CXCL9 Axis Dependence in Mice
por: Xu, Zhentian, et al.
Publicado: (2023)

Synthetic Toll Like Receptor-4 (TLR-4) Agonist Peptides as a Novel Class of Adjuvants
por: Shanmugam, Arulkumaran, et al.
Publicado: (2012)

Disulfiram/Copper Induces Immunogenic Cell Death and Enhances CD47 Blockade in Hepatocellular Carcinoma
por: Gao, Xingxing, et al.
Publicado: (2022)

GITR Promotes the Polarization of TFH-Like Cells in Helicobacter pylori-Positive Gastritis
por: Ming, Siqi, et al.
Publicado: (2021)

Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers
por: Mai, Chun Wai, et al.
Publicado: (2013)

TLR3 agonism re‐establishes CNS immune competence during α4‐integrin deficiency
por: Hussain, Rehana Z., et al.
Publicado: (2018)

Toll-Like Receptor 4 (TLR4) and Typhoid Fever in Vietnam
por: Hue, Nguyen Thi, et al.
Publicado: (2009)

NEDD4 Negatively Regulates GITR via Ubiquitination in Immune Microenvironment of Melanoma
por: Guo, Yu, et al.
Publicado: (2019)

Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy
por: Shrimali, Rajeev, et al.
Publicado: (2017)

Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression
por: Giurini, Eileena F., et al.
Publicado: (2022)

Toll-Like Receptor 4 (TLR4) Expression Affects Schwann Cell Behavior in vitro
por: Zhang, Huanhuan, et al.
Publicado: (2018)

The Role of GITR/GITRL Interaction in Autoimmune Diseases
por: Tian, Jie, et al.
Publicado: (2020)

Phylogenetic variation and polymorphism at the Toll-like receptor 4 locus (TLR4)
por: Smirnova, Irina, et al.
Publicado: (2000)

Toll-Like Receptor 4 (TLR4) and AMPK Relevance in Cardiovascular Disease
por: Vaez, Haleh, et al.
Publicado: (2023)

Toll-like receptor 4 (TLR4): new insight immune and aging
por: Kim, Hyo-Jin, et al.
Publicado: (2023)

Toll-Like Receptor 4 Expression on Lymphoma Cells Is Critical for Therapeutic Activity of Intratumoral Therapy With Synthetic TLR4 Agonist Glucopyranosyl Lipid A
por: Lu, Hailing, et al.
Publicado: (2020)

High-level of intratumoral GITR+ CD4 T cells associate with poor prognosis in gastric cancer
por: Ke, Shouyu, et al.
Publicado: (2022)

Structural basis of peptidomimetic agonism revealed by small-molecule GLP-1R agonists Boc5 and WB4-24
por: Cong, Zhaotong, et al.
Publicado: (2022)

MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential
por: Tigue, Natalie J., et al.
Publicado: (2017)

Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery
por: Narumi, Kenta, et al.
Publicado: (2019)

CD8(+) T Cells: GITR Matters
por: Ronchetti, Simona, et al.
Publicado: (2012)

Toll-Like Receptor (TLR) 2 and TLR4 Differentially Regulate Doxorubicin Induced Cardiomyopathy in Mice
por: Ma, Yonggang, et al.
Publicado: (2012)

NOD2 Agonist Promotes the Production of Inflammatory Cytokines in VSMC in Synergy with TLR2 and TLR4 Agonists
por: Sun, Jinghua, et al.
Publicado: (2012)

The TNF receptor-ligands 4-1BB-4-1BBL and GITR-GITRL in NK cell responses
por: Barao, Isabel
Publicado: (2013)

Formulated Phospholipids as Non-Canonical TLR4 Agonists
por: Liang, Hong, et al.
Publicado: (2022)

Toll-Like Receptor (TLR2 and TLR4) Polymorphisms and Chronic Obstructive Pulmonary Disease
por: Budulac, Simona E., et al.
Publicado: (2012)

Expression of Toll-Like Receptors (TLR2 and TLR4) in the Eyes of Mice with Disseminated Acanthamoebiasis
por: Kot, Karolina, et al.
Publicado: (2019)

TLR2 and TLR4 in Parkinson’s disease pathogenesis: the environment takes a toll on the gut
por: Gorecki, Anastazja M., et al.
Publicado: (2021)

Endotoxin-tolerant Mice Have Mutations in Toll-like Receptor 4 (Tlr4)
por: Qureshi, Salman T., et al.
Publicado: (1999)

The Role of Carbohydrates in the Lipopolysaccharide (LPS)/Toll-Like Receptor 4 (TLR4) Signalling
por: Cochet, Florent, et al.
Publicado: (2017)

Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation
por: Tam, Janine S. Y., et al.
Publicado: (2021)

Phytochemicals targeting Toll-like receptors 4 (TLR4) in inflammatory bowel disease
por: Dai, Wenbin, et al.
Publicado: (2022)

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3(+)CD25(+)CD4(+) regulatory T cells
por: Ko, Kuibeom, et al.
Publicado: (2005)

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3(+)CD25(+)CD4(+) regulatory T cells
por: Ko, Kuibeom, et al.
Publicado: (2012)

Correction: Toll-Like Receptor (TLR) 2 and TLR4 Differentially Regulate Doxorubicin Induced Cardiomyopathy in Mice
por: Ma, Yonggang, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_uk9ojoduts504cba0aeb999v0k